Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance
CorMedix Inc. (CRMD)
NASDAQ:AMEX Investor Relations:
cormedix.com
Company Research
Source: GlobeNewswire
? Q1 2025 Unaudited Net Revenue of $39.0 million ? ? Expected Q1 Adjusted EBITDA above $22.5 million ? ? Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ? BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited first quarter results and provides an update on its business. These include the following key updates: CorMedix announces preliminary, unaudited net revenue of $39.0 million for 1Q 2025, and expects 1Q 2025 adjusted EBITDA(1) to exceed $22.5 million once final numbers are reported.Since providing initial guidance, the Company received larger than expected orders during the final week of March, and has also obtained additional visibility into inventory levels on hand at some of our current purchasing customers. Based on this new inf
Show less
Read more
Impact Snapshot
Event Time:
CRMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRMD alerts
High impacting CorMedix Inc. news events
Weekly update
A roundup of the hottest topics
CRMD
News
- 5 High Earnings Yield Value Picks Ahead of Key Economic Reports [Yahoo! Finance]Yahoo! Finance
- Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value? [Yahoo! Finance]Yahoo! Finance
- Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ... [Yahoo! Finance]Yahoo! Finance
- Does the Recent 9.9% Pullback Make CorMedix a Bargain in 2025? [Yahoo! Finance]Yahoo! Finance
- Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025 [Yahoo! Finance]Yahoo! Finance
CRMD
Earnings
- 11/12/25 - Beat
CRMD
Sec Filings
- 12/11/25 - Form 4
- 12/10/25 - Form 4
- 12/9/25 - Form 144
- CRMD's page on the SEC website